2017 FDA New Cancer Treatment Approvals Roundup…So Far

April 24, 2017

Cancer research is on a roll! It’s a very exciting time for cancer research and drug development. In 2016, the United States Food and Drug Administration (FDA) made 19 new approval for cancer drugs. In 2017, there have already been nine new drugs or new indications for existing drugs approved for cancer treatment by the FDA. Follow the links to the American Society of Clinical Oncology website to learn more about each approval below.

January

Ibrutinib—relapsed/refractory marginal zone lymphoma

February

Nivolumab— advanced bladder cancer

Lenalidomide—multiple myeloma maintenance therapy after autologous stem cell transplant

March

Osimertinib—advanced non-small cell lung cancer with the EGFR T790M mutation

Niraparib—recurrent epithelial ovarian, fallopian tube, or peritoneal cancer

Avelumab—metastatic Merkel call carcinoma (a type of skin cancer)

Ribociclib—hormone receptor positive, HER2-negative advanced breast cancer

Pembrolizumab—relapsed or refractory classical Hodgkin lymphoma

April

Atezolizumab—initial treatment for advanced bladder cancer

 

To learn more about the importance of clinical trials and the clinical trials approval process, visit My PearlPoint